We knew the CF33 is powerful itself and also crucial to the be succeeded in novel therapies CF33-CD19
and
Our management had a pre-IND meeting with FDA and received feedback and guidance back in Aug 2020
This important feedback from FDA would provide us with a clear roadmap for a successful IND submission and clinical development of CF33
Since we are in-licencing CF33 about 1.5 years ago, our management took every step seriously and carefully to make sure we will have a successful and fast pathway and now we are at the doorstep
The IND approvals will be announced soon, any days
Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS, page-286
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.003(5.77%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.7¢ | 5.2¢ | $802.5K | 14.79M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 348447 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 1214875 | 6 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |